(Q52596335)

PubMed publication ID

29634946

4 May 2018

http://europepmc.org/abstract/MED/29634946

title

Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC5896787&resulttype=core&format=json

11 May 2020

3

Jedd D Wolchok

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC5896787&resulttype=core&format=json

11 May 2020

author name string

Roberta Zappasodi

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC5896787&resulttype=core&format=json

11 May 2020

Taha Merghoub

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC5896787&resulttype=core&format=json

11 May 2020

publication date

1 April 2018

1 reference

PubMed publication ID

29634946

4 May 2018

http://europepmc.org/abstract/MED/29634946

published in

Cancer Cell

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC5896787&resulttype=core&format=json

11 May 2020

volume

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC5896787&resulttype=core&format=json

11 May 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC5896787&resulttype=core&format=json

11 May 2020

page(s)

581-598

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC5896787&resulttype=core&format=json

Graft-versus-leukemia reactions after bone marrow transplantation

11 May 2020

cites work

1 reference

12 December 2020

Stimulation of CD28 triggers an association between CD28 and phosphatidylinositol 3-kinase in Jurkat T cells

1 reference

12 December 2020

CTLA-4 can function as a negative regulator of T cell activation

1 reference

12 December 2020

Transforming growth factor-beta activation in irradiated murine mammary gland

1 reference

12 December 2020

Binding of phosphatidylinositol-3-OH kinase to CD28 is required for T-cell signalling

1 reference

12 December 2020

Enhancement of antitumor immunity by CTLA-4 blockade

1 reference

12 December 2020

CD28/B7 system of T cell costimulation

1 reference

12 December 2020

Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor

1 reference

12 December 2020

Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice

1 reference

12 December 2020

Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation

1 reference

12 December 2020

The role of CTLA-4 in induction and maintenance of peripheral T cell tolerance

1 reference

12 December 2020

The CD28 signaling pathway regulates glucose metabolism

1 reference

12 December 2020

Expression of programmed death 1 ligands by murine T cells and APC

1 reference

12 December 2020

Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses

1 reference

12 December 2020

Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy

1 reference

12 December 2020

Treatment of murine leukaemia with X rays and homologous bone marrow; preliminary communication.

1 reference

12 December 2020

Cancer; a biological approach. I. The processes of control

1 reference

12 December 2020

Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated

1 reference

12 December 2020

The three Es of cancer immunoediting

1 reference

12 December 2020

Cancer immunotherapy: moving beyond current vaccines

1 reference

12 December 2020

Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer

1 reference

12 December 2020

Mechanisms of type-I- and type-II-interferon-mediated signalling

1 reference

12 December 2020

Establishment of NOD-Pdcd1-/- mice as an efficient animal model of type I diabetes

1 reference

12 December 2020

CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms

1 reference

12 December 2020

Tumor-derived lactic acid modulates dendritic cell activation and antigen expression.

1 reference

12 December 2020

Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy

1 reference

12 December 2020

Epigenetic regulation of X-linked cancer/germline antigen genes by DNMT1 and DNMT3b

1 reference

12 December 2020

Cancer regression in patients after transfer of genetically engineered lymphocytes

1 reference

12 December 2020

Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway.

1 reference

12 December 2020

Calreticulin exposure dictates the immunogenicity of cancer cell death

1 reference

12 December 2020

Inhibitory effect of tumor cell-derived lactic acid on human T cells

1 reference

12 December 2020

Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

1 reference

12 December 2020

A potential role for epigenetic modulatory drugs in the enhancement of cancer/germ-line antigen vaccine efficacy

1 reference

12 December 2020

II. Contribution to the Knowledge of Sarcoma

1 reference

12 December 2020

PD-1 and its ligands in tolerance and immunity

1 reference

12 December 2020

Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity

1 reference

12 December 2020

Glucose uptake is limiting in T cell activation and requires CD28-mediated Akt-dependent and independent pathways.

1 reference

12 December 2020

Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells.

1 reference

12 December 2020

Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways.

1 reference

12 December 2020

HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance

1 reference

12 December 2020

CTLA-4 control over Foxp3+ regulatory T cell function

1 reference

12 December 2020

Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice

1 reference

12 December 2020

Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection.

1 reference

12 December 2020

The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation

1 reference

12 December 2020

Enhancing CD8 T-cell memory by modulating fatty acid metabolism

1 reference

12 December 2020

The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment

1 reference

12 December 2020

Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody

1 reference

12 December 2020

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

1 reference

12 December 2020

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

12 December 2020

Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function

1 reference

12 December 2020

In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study

1 reference

12 December 2020

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

1 reference

12 December 2020

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

1 reference

12 December 2020

1 reference

12 December 2020

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

1 reference

12 December 2020

Tumor lactic acidosis suppresses CTL function by inhibition of p38 and JNK/c-Jun activation

1 reference

12 December 2020

TOR in the immune system

1 reference

12 December 2020

A decade of exploring the cancer epigenome - biological and translational implications

1 reference

12 December 2020

Immunologic correlates of the abscopal effect in a patient with melanoma

1 reference

12 December 2020

Positive conversion of negative signaling of CTLA4 potentiates antitumor efficacy of adoptive T-cell therapy in murine tumor models.

1 reference

12 December 2020

Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2.

1 reference

12 December 2020

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

1 reference

12 December 2020

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

1 reference

12 December 2020

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

1 reference

12 December 2020

Regulatory T cells in radiotherapeutic responses

1 reference

12 December 2020

Metformin and cancer: from the old medicine cabinet to pharmacological pitfalls and prospects

1 reference

12 December 2020

Metabolic regulation of T lymphocytes

1 reference

12 December 2020

Inhibition of both BRAF and MEK in BRAF(V600E) mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties.

1 reference

12 December 2020

BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.

1 reference

12 December 2020

A systemic complete response of metastatic melanoma to local radiation and immunotherapy.

1 reference

12 December 2020

Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy

1 reference

12 December 2020

CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer

1 reference

12 December 2020

Molecular mechanisms of T cell co-stimulation and co-inhibition

1 reference

12 December 2020

Interplay between the cancer genome and epigenome

1 reference

12 December 2020

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

1 reference

12 December 2020

Nivolumab plus ipilimumab in advanced melanoma

1 reference

12 December 2020

AMPK: a target for drugs and natural products with effects on both diabetes and cancer

1 reference

12 December 2020

Tumor-derived lactate modifies antitumor immune response: effect on myeloid-derived suppressor cells and NK cells

1 reference

12 December 2020

Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells

1 reference

12 December 2020

Signatures of mutational processes in human cancer

1 reference

12 December 2020

Dendritic cell reprogramming by endogenously produced lactic acid.

1 reference

12 December 2020

Targeting lactate metabolism for cancer therapeutics

1 reference

12 December 2020

Potential applications for biguanides in oncology

1 reference

12 December 2020

Human T cells engineered to express a programmed death 1/28 costimulatory retargeting molecule display enhanced antitumor activity.

1 reference

12 December 2020

Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma

1 reference

12 December 2020

Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors

1 reference

12 December 2020

Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer.

1 reference

12 December 2020

Phenformin enhances the therapeutic benefit of BRAF(V600E) inhibition in melanoma

1 reference

12 December 2020

Alterations of immune response of Non-Small Cell Lung Cancer with Azacytidine

1 reference

12 December 2020

Low-dose irradiation programs macrophage differentiation to an iNOS⁺/M1 phenotype that orchestrates effective T cell immunotherapy

1 reference

12 December 2020

A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application

1 reference

12 December 2020

Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer

1 reference

12 December 2020

Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial

1 reference

12 December 2020

Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice.

1 reference

12 December 2020

Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitor

1 reference

12 December 2020

Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs

1 reference

12 December 2020

Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer

1 reference

12 December 2020

An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer.

1 reference

12 December 2020

Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers.

1 reference

12 December 2020

Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival

1 reference

12 December 2020

Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors

1 reference

12 December 2020

Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges

1 reference

12 December 2020

Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells

1 reference

12 December 2020

Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy.

1 reference

12 December 2020

Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor

1 reference

12 December 2020

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma

1 reference

12 December 2020

Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade.

1 reference

12 December 2020

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

1 reference

12 December 2020

PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients

1 reference

12 December 2020

Nivolumab in previously untreated melanoma without BRAF mutation

1 reference

12 December 2020

Genetic basis for clinical response to CTLA-4 blockade in melanoma

1 reference

12 December 2020

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

1 reference

12 December 2020

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

1 reference

12 December 2020

STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors.

1 reference

12 December 2020

A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response

1 reference

12 December 2020

mTOR inhibition improves immune function in the elderly

1 reference

12 December 2020

Immune-mediated antitumor effect by type 2 diabetes drug, metformin

1 reference

12 December 2020

Histone deacetylase inhibitors prevent activation-induced cell death and promote anti-tumor immunity

1 reference

12 December 2020

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

1 reference

12 December 2020

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

1 reference

12 December 2020

Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma

1 reference

12 December 2020

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

1 reference

12 December 2020

PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation

1 reference

12 December 2020

TGFβ Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity

1 reference

12 December 2020

Pembrolizumab versus Ipilimumab in Advanced Melanoma

1 reference

12 December 2020

Pembrolizumab for the treatment of non-small-cell lung cancer

1 reference

12 December 2020

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

1 reference

12 December 2020

Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

1 reference

12 December 2020

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

1 reference

12 December 2020

Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer

1 reference

12 December 2020

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

1 reference

12 December 2020

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

1 reference

12 December 2020

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

1 reference

12 December 2020

Decitabine Enhances Lymphocyte Migration and Function and Synergizes with CTLA-4 Blockade in a Murine Ovarian Cancer Model.

1 reference

12 December 2020

Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial.

1 reference

12 December 2020

NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma.

1 reference

12 December 2020

HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade.

1 reference

12 December 2020

DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts.

1 reference

12 December 2020

Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses

1 reference

12 December 2020

Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression

1 reference

12 December 2020

Oncolytic viruses: a new class of immunotherapy drugs

1 reference

12 December 2020

Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma

1 reference

12 December 2020

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

1 reference

12 December 2020

Essential role of HDAC6 in the regulation of PD-L1 in melanoma

1 reference

12 December 2020

Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma.

1 reference

12 December 2020

Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy

1 reference

12 December 2020

MCT1 Modulates Cancer Cell Pyruvate Export and Growth of Tumors that Co-express MCT1 and MCT4

1 reference

12 December 2020

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

1 reference

12 December 2020

MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade

1 reference

12 December 2020

Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma

1 reference

12 December 2020

EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.

1 reference

12 December 2020

Combined IL-21-primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient

1 reference

12 December 2020

T-Cell Therapy Using Interleukin-21-Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression

1 reference

12 December 2020

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

1 reference

12 December 2020

Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition

1 reference

12 December 2020

LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells

1 reference

12 December 2020

Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy

1 reference

12 December 2020

Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells.

1 reference

12 December 2020

Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-Analysis.

1 reference

12 December 2020

Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade

1 reference

12 December 2020

Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures

1 reference

12 December 2020

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.

1 reference

12 December 2020

T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer.

1 reference

12 December 2020

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy

1 reference

12 December 2020

TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy

1 reference

12 December 2020

T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition.

1 reference

12 December 2020

Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent.

1 reference

12 December 2020

CIMAvax-EGF: A New Therapeutic Vaccine for Advanced Non-Small Cell Lung Cancer Patients

1 reference

12 December 2020

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response.

1 reference

12 December 2020

Phenformin Inhibits Myeloid-Derived Suppressor Cells and Enhances the Anti-Tumor Activity of PD-1 Blockade in Melanoma

1 reference

12 December 2020

Prognostic significance of PD-L1 in solid tumor: An updated meta-analysis

1 reference

12 December 2020

Chromatin states define tumour-specific T cell dysfunction and reprogramming.

1 reference

12 December 2020

Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy

1 reference

12 December 2020

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.

1 reference

12 December 2020

First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.

1 reference

12 December 2020

De Novo Epigenetic Programs Inhibit PD-1 Blockade-Mediated T Cell Rejuvenation

1 reference

12 December 2020

1 reference

12 December 2020

Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study

1 reference

12 December 2020

An immunogenic personal neoantigen vaccine for patients with melanoma

1 reference

12 December 2020

Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer.

1 reference

12 December 2020

Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis

1 reference

12 December 2020

Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient.

1 reference

12 December 2020

Concurrent PD-1 Blockade Negates the Effects of OX40 Agonist Antibody in Combination Immunotherapy through Inducing T-cell Apoptosis

1 reference

12 December 2020

Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40.

1 reference

12 December 2020

Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.

1 reference

12 December 2020

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

1 reference

12 December 2020

Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma.

1 reference

12 December 2020

Mechanisms regulating T-cell infiltration and activity in solid tumors.

1 reference

12 December 2020

Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors.

1 reference

12 December 2020

A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy.

1 reference

12 December 2020

Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer.

1 reference

12 December 2020

Differential binding affinity of mutated peptides for MHC class I is a predictor of survival in advanced lung cancer and melanoma

1 reference

12 December 2020

10.1016/J.CCELL.2018.03.005

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC5896787&resulttype=core&format=json

11 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC5896787&resulttype=core&format=json

11 May 2020

PubMed publication ID

29634946

1 reference